Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.5.3079

Endostar Combined with Cisplatin Inhibits Tumor Growth and Lymphatic Metastasis of Lewis Lung Carcinoma Xenografts in Mice  

Dong, Xiao-Peng (Department of Thoracic Surgery, Second Hospital of Shandong University, Shandong University)
Xiao, Tian-Hui (Department of Thoracic Surgery, Second Hospital of Shandong University, Shandong University)
Dong, Hong (Department of Thoracic Surgery, Second Hospital of Shandong University, Shandong University)
Jiang, Ning (Department of Thoracic Surgery, Second Hospital of Shandong University, Shandong University)
Zhao, Xiao-Gang (Department of Thoracic Surgery, Second Hospital of Shandong University, Shandong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.5, 2013 , pp. 3079-3083 More about this Journal
Abstract
Objective: To investigate the effects of endostar, a recombined humanized endostatin, plus cisplatin on the growth, lymphangiogenesis and lymphatic metastasis of the Lewis lung carcinoma (LLC) in mice. Methods: A tumor model were established in C57BL/6 mice by intravenious transplantation of LLC cells. Then the mice were randomized to receive administration with NS, endostar, cisplatin, or endostar plus cisplatin. After the mice were sacrificed, tumor multiplicity, tumor size and lymph node metastasis were assessed. Then the expression of vascular endothelial growth factor-c (VEGF-C) and podoplanin were determined by immunohistochemical staining. Results: Endostar plus cisplatin significantly suppressed tumor growth. lymphatic metastasis and prolonged survival time of the mice without obvious toxicity. The inhibition of lymphatic metastasis was associated with decreased microlymphatic vessel density (MLVD) and expression of VEGF-C. Conclusions: Endostar combined with cisplatin was more effective to suppress tumor growth and lymphatic metastasis than either agent alone. Thus this may provide a rational alternative for lung carcinoma treatment.
Keywords
Lung tumor; endostatin; cisplatin; lymphangiogenesis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Brideau G, Makinen MJ, Elamaa H, et al (2007). Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res, 67, 11528-35.   DOI   ScienceOn
2 Boehm T, Folkman J, Browder T, et al (1997). Antiangiogenic therapy of experimental cancer dose not induce acquired drug resistance. Nature, 390, 404-7.   DOI   ScienceOn
3 Cheng K, Zhao F, Gao F, et al (2012). Factors potentially associated with chemotherapy-induced anemia in patients with solid cancers. Asian Pac J Cancer Prev, 13, 5057-61.   DOI   ScienceOn
4 Detmar M, Hirakawa S (2002). The formation of lymphatic vessels and its importance in the setting of malignancy. J Exp Med, 196, 713-8.   DOI   ScienceOn
5 Folkman J (2006). Angiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res, 312, 594-607.   DOI   ScienceOn
6 Fukumoto S, Morifuji M, Katakura Y, et al (2005). Endostatin inhibits lymph node metastasis by a down-regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis, 22, 31-8.   DOI   ScienceOn
7 Han Q, Fu Y, Zhou H, et al (2007). Contributions of Zn (II)-binding to the structural stability of endostatin. FEBS Lett, 581, 3027-32.   DOI   ScienceOn
8 Huang G, Chen L (2010). Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol, 136, 1201-11.   DOI   ScienceOn
9 Klement G, Huang P, Mayer B, et al (2002). Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res, 8, 221-32.
10 Krishnan J, Kirkin V, Steffen A, et al (2003). Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res, 63, 713-22.
11 Ling Y, Yang Y, Lu N, et al (2007). Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun, 361, 79-84.   DOI   ScienceOn
12 Liu ZY, Qiu HO, Yuan XJ,et al (2012). Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol, 41, 1762-72.
13 Makinen T, Jussila L, Veikkola T (2001). Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med, 7, 199-205.   DOI   ScienceOn
14 Ma X, Yao Y, Yuan D, et al (2012). Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS One, 7, e53449.   DOI
15 Miller KD, Sweeney CJ, Sledge GW (2001). Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol, 19, 1195-206.
16 Nyberg P, Xie L, Kalluri R (2005). Endogenous inhibitors of angiogenesis. Cancer Res, 65, 3967-79.   DOI   ScienceOn
17 Shimizu K, Kubo H, Yamaguchi K (2004). Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci, 5, 328-33.
18 O'Reilly MS, Boehm T, Shing Y(1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.   DOI   ScienceOn
19 Rong B, Yang S, Li W, et al (2012). Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol, 24, 170.
20 Shao XJ, Xie FM(2005). Influence of angiogenesis inhibitors, endostatin and PF-4, on lymphangiogenesis. Lymphology, 38, 1-8.
21 Sun Y, Wang J, Liu Y, et al (2005). Results of phase III trial of rhendostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. Annual ASCO Meeting, May in FL, USA.
22 Wakisaka N, Hirota K, Kondo S, et al (2012). Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma. Oral Oncol, 48, 703-8.   DOI   ScienceOn
23 Wang Z, Chen Y, Li X, et al (2012). Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. Asian Pac J Cancer Prev, 13, 27-31.   DOI   ScienceOn
24 Yancopoulos GD, Davis S, Gale NW(2000). Vascular-speciflc growth factors and blood vessel formation. Nature, 407, 242-8.   DOI   ScienceOn